Hanover, NJ: Novartis Pharmaceuticals Corporation, 2015. 148. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920 6. 149. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in pa- tients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103 11. 150. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin- angiotensin system inhibition for the treatment of heart failure. J Am Coll Cardiol HF. 2014;2:663 70. 151. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet. 2000;356:608 9. 152. Braunwald E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol. 2015;65:1029 41. 153. Ruilope LM, Dukat A, B hm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active com- parator study. Lancet. 2010;375:1255 66. 154. Bohm M, Robertson M, Ford I, et al. Influence of cardiovascular and non- cardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). Am J Cardiol. 2015;116:1890 7. 155. Swedberg K, Komajda M, B hm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875 85. 156. Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091 9. 157. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coro- nary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372: 807 16. 158. Pitt B, Segal R, Martinez FA, et al. 